Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + capecitabine in HER2-low advanced breast cancer
NCT05845138Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Started Jul 2023; status: recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05845138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05845138.